<DOC>
	<DOCNO>NCT02059187</DOCNO>
	<brief_summary>This 24-week study safety efficacy comparison MK-1293 Lantus™ participant type 2 diabetes mellitus ( T2DM ) . The primary hypothesis 24 week , mean change hemoglobin A1c ( A1C ) baseline non-inferior ( margin 0.4 % ) participant treat MK-1293 compare participant treat Lantus™ .</brief_summary>
	<brief_title>The Safety Efficacy MK-1293 Versus Lantus™ Participants With Type 2 Diabetes Mellitus ( MK-1293-006 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Diagnosis Type 2 Diabetes Mellitus ( T2DM ) define American Diabetes Association ( ADA ) European Association Study Diabetes ( EASD ) hemoglobin A1C ≤11.0 % require insulin glycemic control Body mass index ( BMI ) &lt; 45 kg/m^2 History type 1 diabetes mellitus history ketoacidosis , type 1 diabetes confirm Cpeptide &lt; 0.7 ng/mL ( 0.23 nmol/L ) One severe hypoglycemic episode associate hypoglycemic seizure , coma unconsciousness within past 6 month History intolerance hypersensitivity Lantus™ contraindication Lantus™ one excipients base label country investigational site On weight loss program within last 8 week Received injectable incretinbased therapy ( e.g. , Victoza™ , Byetta™ ) within prior 8 week Bariatric surgery within 12 month prior sign inform consent Likely require treatment ≥2 consecutive week repeat course corticosteroid Undergone surgical procedure within 4 week prior sign inform consent plan major surgery study New worsen sign symptom coronary heart disease congestive heart failure within last 3 month Presence follow last 3 month : acute coronary syndrome , coronary artery intervention , and/or stroke transient ischemic neurological disorder Severe peripheral vascular disease Systolic blood pressure ≥ 160 mm Hg diastolic ≥95 mm Hg blood pressure consider likely limit adjustment antihypertensive medication Chronic myopathy progressive neurological neuromuscular disorder Active nephropathy History active liver disease ( nonalcoholic hepatic steatosis ) , include chronic active hepatitis B C , primary biliary cirrhosis , symptomatic gallbladder disease Human immunodeficiency virus ( HIV ) Clinically important hematological disorder ( aplastic anemia , myeloproliferative myelodysplastic syndrome , thrombocytopenia ) History malignancy ≤5 year prior sign inform consent , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer History melanoma , leukemia , lymphoma , renal cell carcinoma Hyperthyroidism On stable dose thyroid hormone replacement therapy &lt; 6 week Uses recreational illicit drug recent history ( within last year ) drug alcohol abuse dependence Pregnant breastfeeding , expect conceive donate egg study , include 14 day follow last dose study drug Donated blood product phlebotomy &gt; 300 mL within 8 week sign informed consent , intend donate blood product within project duration study Poor mental function reason expect participant may difficulty comply requirement study Clinically significant ECG abnormality expose participant risk enrol study Positive urine pregnancy test Participant night shift worker cause difficulty comply overnight fast requirement potential confound 7point SMBG analysis Participant , assess investigator , appropriate agree target fast glucose 70100 mg/dL [ 3.9 5.6 mmol/L ] Has use formulation glargine insulin Lantus™</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>